Flutamide: An Antiandrogen for Advanced Prostate Cancer

  title={Flutamide: An Antiandrogen for Advanced Prostate Cancer},
  author={Barry R. Goldspiel and David R. Kohler},
  journal={Annals of Pharmacotherapy},
  pages={616 - 623}
Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of dihydrotestosterone to the target cell receptor, thus interfering with androgen action. Flutamide is well absorbed orally and extensively metabolized; its active metabolite, 2-hydroxyflutamide, is formed rapidly and excreted almost entirely by the kidneys. Clinical studies in prostate cancer patients have demonstrated efficacy with flutamide monotherapy in patients who had received no prior… 

Tables from this paper

Androgen Deprivation Therapy for Advanced Prostate Cancer
For men with castrate-resistant prostate cancer (CRPC), new treatment options with overall survival benefit are available including combined treatment with abiraterone and enzalutamide, nonhormonal therapies like chemotherapy with docetaxel and cabazitaxel, vaccine, and radium-223.
Lack of Methemoglobinemia with Flutamide
This study found no clinically relevant increase of Met-Hb concentrations in elderly patients with prostatic cancer during chronic treatment with flutamide, however, clinicians should be aware of the very rare possibility of flUTamide-induced methemoglobinemia.
Survivin mediates resistance to antiandrogen therapy in prostate cancer
The study indicates that upregulation of Survivin via IGF-1 signaling confers resistance to Flutamide in prostate cancer cells, supporting a novel mechanism of resistance to antiandrogen therapy.
Androgen Deprivation for Prostatic Carcinoma: A Rationale for Choosing Components
  • R. Fourcade, C. Chatelain
  • Medicine, Biology
    International journal of urology : official journal of the Japanese Urological Association
  • 1998
Ever since prostatic carcinoma was discovered to be dependent on the hormone androgen for its proliferation, androgen deprivation has been the treatment of choice for advanced cases of prostate
Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
The importance of androgen signaling in prostate cancer biology and advances made over the years to effectively target this signaling pathway are described and the potential of this knowledge for translation into future therapies for prostate cancer is discussed.
Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
An overview of the mutation based resistance of the current clinically used antiandrogens and the rational drug design to overcome the resistance is given, which provides a promising strategy for the development of the new generation of antiandrogen targeting HBP.
Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer
Evidence is provided of sex-hormone mediated regulation of immune checkpoint molecules in vitro with potential ramification for immunotherapies and a potential role for AR activity in PD-L1 regulation.
Disrupting Androgen Receptor Transactivation Domains to Identify Lead Compounds with Potential to be Optimized and Developed into Prostate Cancer Therapeutics
A screening paradigm to identify compounds with novel mechanisms of action to prevent or delay resistance to castration resistant prostate cancer is designed, which would prevent the transcription of both AR-FL and AR-V7 thereby providing a dual approach to preventing CRPC progression.
Modulation of Ovarian Structure and Abdominal Obesity in Curcumin- and Flutamide-treated Aging FSH-R Haploinsufficient Mice
Changes in ovarian histology and oocyte components as well as adipose tissue indicate the potential for reversing ovarian decline and metabolism because of mild hyperandrogenemia that occurs with aging in follicle-stimulating hormone receptor haploinsufficienct mice.


A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
Clinical applications of antiandrogens.
  • M. Namer
  • Biology, Medicine
    Journal of steroid biochemistry
  • 1988
Antiandrogens in Combination with LH‐RH Agonists in Prostate Cancer
  • J. Raynaud
  • Biology, Medicine
    American journal of clinical oncology
  • 1988
The results of randomized clinical studies with the combination of “nonsteroid antiandrogen + LH-RH-A” have established a definite trend toward greater efficacy of the combined treatment over monotherapy, and further data are needed to confirm this trend.
Plasma levels of hydroxy‐flutamide in patients with prostatic cancer receiving the combined hormonal therapy: An LHRH agonist and flutamide
It is observed that two to four hours after oral administration of 250 mg of flutamide to healthy young men, as well as to patients with prostate cancer, the plasma concentration of Flu‐OH reaches a peak at approximately 1.7 μM, and it is extremely important to maintain this concentration of the antiandrogen in plasma constant.
New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%‐70% as reported by many groups using the previous partial hormonal therapy.
Benefits of combination therapy with flutamide in patients relapsing after castration.
Combination therapy with Flutamide and castration (surgical or LHRH agonist) appears to be the treatment of choice for prostate cancer patients in relapse after standard endocrine therapy.